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SEVERE prolonged hypoglycaemia in infancy due to hyperinsulinism does not
always respond to treatment with glucocorticoids or glucagon. Baker et al in
1967 suggested that diazoxide might be used as an alternative method of treat-
ment.
Diazoxide is a benzothiadiazine derivative, chemically closely related to thia-
zide diuretics but lacking diuretic activity. Fajans et al (1968) have recorded
this agent's ability of supress insulin release from normal and abnormal islet
cell tissue. This property was exploited in the treatment of our patient, a 16
week-old infant with severe, prolonged symtomatic hypoglycaemia. Unfortunate
adverse effects of the treatment included hyperosmolar non-ketotic hyper-
glycaemia and marked hirsutism.
CASE REPORT
A 16 week-old male infant was referred from a peripheral hospital for investi-
gation following a convulsion during which his plasma glucose was unrecordable.
He had been delivered normally at term after an uneventful pregnancy and
weighed 3.5 kgs. There were no problems in the neonatal period. He was the
second child of healthy unrelated parents with no family history of diabetes,
epilepsy or unexplained infant deaths.
At the age of 4 weeks he had a brief hospital admission with an upper respir-
atory tract infection and at that time appeared developmentally normal. During
the following months he was brought to his family doctor on several occasions
with episodes which his mother called "colic". During these attacks he screamed,
became rigid and later appeared drowsy. She also reported that he was an ex-
ceptionally hungry baby demanding frequent large feeds of cow's milk and cereal.
On admission he was at the 97th centile for height and weight (Tanner and
Whitehouse, 1966) and his head circumference was on the 90th centile (Westrup
and Barber, 1956). He was an obese hypotonic infant. There were no demon-
strable tendon reflexes or response to stimuli other than pain. Complete head
lag and palmar thumbing were noted but there were no localising neurological
signs. The fundi were normal and there were no cataracts. The liver was palpable
one finger breadth below the costal margin and there was no clinical evidence
of visceromegaly and this was later confirmed by barium meal and intravenous
pyelogram.
123He continued to have focal left-sided convulsions after admission when his
plasma glucose was found to be 0.5 mmol/l. Initial treatment was with a con-
tinuous intraveous infusion of 20 per cent dextrose with a total of 125 mls of
50 per cent dextrose given intermittently. This regimen maintained the plasma
glucose between 1.0-1.5 mmol/l, reaching a peak of 2.0 mmol/l on one occasion.
Full investigations were performed during the first few days following admsisr
sion but failed to establish evidence of hepatic disease or enzyme deficiency
including galactosaemia and glycogen storage disease. Inborn errors of amino
acid metabolism were excluded. EEG and all other neurological investigations
revealed no abnormality. Endocrine studies other than insulin levels were
normal. There was no response to a low leucine diet.
Intravenous dextrose was discontinued for 8 hours before measurement of
plasma insulin. Inappropriate levels of 42 and 44 IU/ml (normal range 10-15
IU/ml) were found on 2 occasions when the plasma glucose levels were less
than 1.0 mmol/l.
Satisfactory control of the hypoglycaemia was not achieved until diazoxide
50 mg. 3 times daily was introduced as therapy. Using this dose, his plasma
glucose was initially maintained at a satisfactory level, but on the 10th day,
this rose over a period of 24 hours to 24 mmol/l. Serum sodium was 154 mmol/l,
urea 25 mmol/l and plasma osmolality was estimated as 352 milliosmols. Diaz-
oxide was discontinued for 36 hours and osmolar correction was achieved
using intravenous 0.45 per cent saline solution and a single dose of 4 units
soluble insulin subcutaneously. Subsequently the diazoxide was recommenced
at 90 mgs, (equivalent to 9 mg/kg per day) in 3 divided doses. The plasma
glucose on this regimen was maintained at a satisfactory level and no further
episodes of hyperglycaemia occurred.
A repeat EEG one month after admission showed a generalised slow wave
abnormality in all regions. Salaam epilepsy developed and was controlled with
clonazepam 0.5 mg twice daily. Unfortunately, despite adequate control of
plasma glucose there was no neurological improvement prior to death. He
remained hypotonic and unresponsive although he sucked well from a bottle.
The head circumference diminished by 1 cm and was only 42 cm at 7 weeks.
Hirsuitism was first noticed after 2 weeks treatment with diazoxide and was
severe after 4 weeks.
Death occurred from an intercurrent chest infection at the age of 7 months.
Permission for a post mortem could not be obtained.
DISCUSSION
Hyperinsulinism was the cause of hypoglycaemia in this case. A compre-
hensive review of the causes of hypoglycaemia was published by Pagliara et al
in 1973. Histological and histochemical studies were suggested, when one wishes
to distinguish between pancreatic B-cell tumours, islet cell hyperplasia, nesi-
dioblastosis and functional disorders causing hyperinsulinism. However, in our
patient a laparotomy was not considered justifiable as irreversable cerebral
124damage had occurred before adequate plasma glucose levels were established
and no improvement was seen in his intellectual development when these were
maintained.
The use of diazoxide in the management of hypoglycaemia of infancy is now
established (Baker et al, 1967; Erhich and Martin, 1969; Marks and Samols,
1968). The condition remains, however, extremely difficult to treat satisfactorily.
Early correction of the plasma glucose remains of major importance in pre-
venting severe brain damage. Diazoxide is perhaps the agent most likely to
achieve this. Drash et al (1968) report many complications of diazoxide includ-
ing hyperglycaemia, ketosis, hirsutism, hyperuricaemia and electrolyte abnor-
malities. They do not record the hyperosmolar condition described here but this
has been reported in adults (Charles and Danforth, 1971). Correction of this
hyperosmolar state is not difficult if diazoxide is withdrawn and adequate intra-
venous fluids administered, insulin was probably not essential in our patient.
The possibility of this potentially lethal complication requires regular monitor-
ing of the serum electrolytes and plasma glucose during the early days and
weeks of treatment. Prevention depends on the use of minimum effective dose
of diazoxide which is probably 7.5 to 12.5 mg/kg per day. Hirsutism is an un-
fortunate but unavoidable complication.
SUMMARY
A 16 week-old infant presented with severe prolonged symptomatic hypo-
glycaemia resistant to the treatment with intravenous dextrose. The aetiology
of the condition was established as hyperinsulinism and treatment was initiated
with diazoxide 15 mg/kg per day, in 3 divided doses. This was shown to be
successful in correction and maintainance of plasma glucose levels initially but
led to the development of a hyperosmolar non-ketotic hyperglycaemic state on
the 10 th day of treatment.
This was readily corrected by discontinuing diazoxide administration, intra-
venous infusion of 0.45 per cent saline solution and subcutaneous insulin. Subse-
quent reduction of diazoxide therapy to 9 mg/kg per day prevented recurrence
of this dangerous complication.
Residual cerebral impairment due to the initial prolonged hypoglycaemia led
eventually to the child's death.
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